Author

G. Rabinovici

h-index 99 View on Semantic Scholar

We have 6 of 784 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Large-scale cerebrospinal fluid proteomics identifies diagnostic biomarker candidates across the clinico-pathological continuum of frontotemporal lobar degeneration

Frontotemporal lobar degeneration (FTLD), predominantly comprised of tau and TDP-43 proteinopathies, is a common cause of early-onset dementia. Biomarkers that reliably classify FTLD subtypes are limited, thereby hindering in-vivo diagnosis and clinical trial stratification. We conducted large-scale, multi-platform cer...

R. Saloner, L. Cornelis, Joshua Downer et al. · bioRxiv · 0 citations

Open access Sep 2026

From neighborhoods to brain health: an outreach model linking health literacy, cognitive care, research, and the arts, in San Francisco

Traditional community outreach, research recruitment, and engagement strategies in aging neuroscience often fail to target and capture the diversity of structural and environmental conditions that shape the risk of age-related neurocognitive disorders (NCDs), including Alzheimer’s disease. In this manuscript, we descri...

S. Lanata, C. Windon, B. Tee et al. · Frontiers in Public Health · 0 citations

Open access Aug 2026

Arterial Spin‐Labeling MRI at the Cortical‐CSF Interface: A Novel Biomarker in Alzheimer Disease

ASL‐derived IF‐perfusion is reduced in AD and may represent a promising imaging marker of altered CSF‐adjacent water transport physiology and further validation against established biomarkers of CSF dynamics and clearance pathways is warranted.

Mona Asghariahmadabad, P. Metanat, Michael Thomas et al. · Annals of Clinical and Trans... · 0 citations

Open access Aug 2026

EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease

Findings support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification and support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification.

T. Paranhos, Yuta Katsumi, M. Brickhouse et al. · Neurology · 0 citations

Open access Jul 2026

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.

A double-cutoff analysis suggest that scans in the 11 to 26 Centiloid range should be interpreted with caution depending on the context of use, and positivity cutoffs converged around 18 Centiloids (data-driven) and 27 Centiloids (visual reads).

G. Blazhenets, D. Soleimani-Meigooni, Konstantinos Chiotis et al. · Journal of the American Medi... · 5 citations

#protein folding Open access Aug 2026

Cerebrospinal fluid YWHAG:NPTX2 ratio predicts clinical severity and future phenoconversion in frontotemporal lobar degeneration

Frontotemporal lobar degeneration (FTLD) is a common cause of early-onset dementias marked by progressive declines in behavior, cognition, and/or movement. FTLD neuropathologies, including TDP-43 proteinopathies and primary tauopathies, do not have reliable fluid biomarkers for in-vivo diagnosis nor biomarkers that dir...

H. Oh, J. Downer, Connor D. Dietz et al. · bioRxiv · 0 citations